Mindset Pharma
Pioneering next-generation psychedelic medicines for neurological and psychiatric disorders.
Market cap
$56.5m
Enterprise value
$51m
Share price
€0.49 9DF.F
loading funding rounds…
| CAD | 2018 | 2019 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (423 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (425 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 189 % | - | - | 189 % |
Source: Company filings or news article
Related Content
More about Mindset Pharma
EditMade with AI
Mindset Pharma is a drug discovery business, based in Toronto, Canada, focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. The Company is traded under the ticker symbol MSET on the CSE
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.